Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 2/2010

01.02.2010 | Original Article

Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy

verfasst von: Christof Schaefer, Reinhard Meister, Corinna Weber-Schoendorfer

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

Apart from thalidomide, retinoids like isotretinoin are the strongest teratogens in humans known today. The overall risk of birth defects is estimated as up to 30% after exposure during embryogenesis. In spite of well established pregnancy prevention programs, pregnancies still occur during isotretinoin therapy in many countries including Germany. A detailed investigation of the incidence and outcome of these pregnancies would fill an important gap.

Methodology

The Berlin Institute for Clinical Teratology documents prospectively the course of drug-exposed pregnancies when contacted for individual drug risk assessment. Datasets of isotretinoin exposed pregnancies recorded between 1993 and 2008 were evaluated as to the outcome of pregnancy.

Results

A total of 108 pregnancies exposed to systemic isotretinoin (median dosage 20 mg/day) during the contraindicated period were registered. 76% (69/91) of the pregnancies with known outcome were electively terminated—mainly for fear of medication risk. No terminations due to abnormal prenatal ultrasound findings were reported. Spontaneous abortions occurred in five pregnancies. Of 18 live births including 1 pair of twins 1 major birth defect (small ventricular septal defect) was observed. None of the infants showed symptoms of retinoid embryopathy. 70% (48/69) of the patients with data on contraception did not use any method, in 30% contraception failed. There was no evidence that poor maternal education was a major cause for the omission of contraception documented in 48 women.

Conclusion

Inadvertent isotretinoin exposure during the first 2 weeks post conception does not necessarily require discussion of termination of pregnancy, as the risk of major birth defects appears to be much lower than it becomes beyond this period. Nevertheless, additional efforts are required to improve the effectiveness of contraception while on isotretinoin treatment considering psycho-social aspects such as improved self-confidence, unexpected new partnership and sexual activity and incorrect perception of infertility.
Literatur
2.
Zurück zum Zitat Adams J (2004) The adverse effect profile of neurobehavioral teratogens: retinoic acid. Birth Defects Res A 70:344 Adams J (2004) The adverse effect profile of neurobehavioral teratogens: retinoic acid. Birth Defects Res A 70:344
3.
Zurück zum Zitat Adams J, Lammer E (1991) Relationship between dysmorphology and neuropsychological functions in children exposed to isotretinoin (in utero). In: Fujii T, Boer GJ (eds) Functional neuroteratology of short term exposure to drugs. Teiko University Press, Tokyo, pp 159–168 Adams J, Lammer E (1991) Relationship between dysmorphology and neuropsychological functions in children exposed to isotretinoin (in utero). In: Fujii T, Boer GJ (eds) Functional neuroteratology of short term exposure to drugs. Teiko University Press, Tokyo, pp 159–168
9.
Zurück zum Zitat Holmes LB (1999) Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 64:79–82 Holmes LB (1999) Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 64:79–82
12.
Zurück zum Zitat Lammer EJ, Chen DT, Hoar RM et al (1985) Retinoic acid embryopathy. N Engl J Med 313:837–841PubMed Lammer EJ, Chen DT, Hoar RM et al (1985) Retinoic acid embryopathy. N Engl J Med 313:837–841PubMed
13.
Zurück zum Zitat Lammer EJ, Hayes AM, Schunior A et al (1988) Unusually high risk for adverse outcomes of pregnancy following fetal isotretinoin exposure. Am J Hum Genet 43:A 58 Lammer EJ, Hayes AM, Schunior A et al (1988) Unusually high risk for adverse outcomes of pregnancy following fetal isotretinoin exposure. Am J Hum Genet 43:A 58
17.
Zurück zum Zitat Moskop JC, Smith ML, De Ville K (1997) Ethical aspects of teratogenic medications: the case of isotretinoin. J Clin Ethics 8:264–278PubMed Moskop JC, Smith ML, De Ville K (1997) Ethical aspects of teratogenic medications: the case of isotretinoin. J Clin Ethics 8:264–278PubMed
18.
Zurück zum Zitat Nulman I, Berkovitch M, Klein J et al (1998) Steady-state pharmacokinetics of isotretinoin and ist 4-oxo metabolite: implications for fetal safety. J Clin Pharmacol 38:926–930PubMed Nulman I, Berkovitch M, Klein J et al (1998) Steady-state pharmacokinetics of isotretinoin and ist 4-oxo metabolite: implications for fetal safety. J Clin Pharmacol 38:926–930PubMed
21.
Zurück zum Zitat Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA (2003) Guidelines for case classification for the national birth defects prevention study. Birth Defects Res A 67:193–201. doi:10.1002/bdra.10012 CrossRef Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA (2003) Guidelines for case classification for the national birth defects prevention study. Birth Defects Res A 67:193–201. doi:10.​1002/​bdra.​10012 CrossRef
Metadaten
Titel
Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy
verfasst von
Christof Schaefer
Reinhard Meister
Corinna Weber-Schoendorfer
Publikationsdatum
01.02.2010
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 2/2010
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-009-1112-2

Weitere Artikel der Ausgabe 2/2010

Archives of Gynecology and Obstetrics 2/2010 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.